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Summary 
Diabetes results in a large health and economic burden for individuals, families and 
communities. There were around 53,500 people in Australia who began using insulin to treat 
their diabetes in 2011― 68% had type 2 diabetes, 12% had gestational diabetes, 4% had type 1 
diabetes and 1% had other forms of diabetes requiring insulin (diabetes type was unknown 
for another 15%).  
This report uses data from the National (insulin-treated) Diabetes Register to examine the 
incidence of insulin-treated diabetes in Australia for the three main types of diabetes. 
Type 1 diabetes  
• In 2011, there were 2,367 new cases of type 1 diabetes in Australia, equating to 11 new 
cases per 100,000 population. This rate has remained stable over the last decade, with 
between 10 and 12 new cases per 100,000 population per year. 
• Half of all new cases of type 1 diabetes were among people aged 18 or under. Rates of 
type 1 diabetes peaked in the 10–14 age group at 32 per 100,000 population: a rate 5 times 
as high as for those aged 40–44. 
• The incidence of type 1 diabetes was higher in males than in females—13 in every 
100,000 males compared with 8 per 100,000 females. 
• The incidence of type 1 diabetes did not vary considerably across the states and 
territories (10–13 per 100,000), except in the Northern Territory where the rate was 
considerably lower at 8 cases per 100,000. Rates of type 1 diabetes also did not vary by 
socioeconomic status. 
• The incidence of type 1 diabetes was lower in Remote and very remote areas (compared 
with other areas in Australia) and was lower for Indigenous Australians compared with 
non-Indigenous Australians. 
Insulin-treated type 2 diabetes 
• In 2011, 36,263 people began using insulin to treat their type 2 diabetes, equating to 
163 people per 100,000 population. 
• The incidence of insulin use for type 2 diabetes increased rapidly with age, with rates 
increasing five–fold between ages 40–44 and 70–74 (100 compared with 550 per 100,000 
population, respectively).  
• Rates were higher among males than females at 185 compared with 140 per 100,000 
population, respectively. 
• Rates of insulin-treated type 2 diabetes were twice as high for those living in the lowest 
socioeconomic status (SES) areas compared with the highest SES areas.  
Insulin-treated gestational diabetes 
• There were 6,362 women aged 15–49 who began using insulin to treat gestational 
diabetes in 2011, equating to 117 per 100,000 women in this age group in Australia. 
• Rates of insulin-treated gestational diabetes varied across states and territories and by 
socioeconomic and geographical areas.  
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1 Introduction 
Diabetes is one of the leading threats to the health of Australians. Not only does it have an 
impact on individual health and wellbeing, but it also has social and economic ramifications 
for families and communities. Diabetes is a chronic condition marked by high levels of 
glucose in the blood. It is caused either by the inability to produce insulin (a hormone 
produced by the pancreas to control blood glucose levels), or by the body not being able to 
use insulin effectively, or both (see Box 1.1 for further details).  
The main types of diabetes are: type 1 diabetes—a lifelong autoimmune disease that usually 
has onset in childhood but can be diagnosed at any age; type 2 diabetes—usually associated 
with lifestyle factors and largely preventable; and gestational diabetes—when higher than 
normal blood glucose is diagnosed in pregnancy (see Glossary for further details). 
Diabetes can lead to a range of health problems, disability, poor quality of life and premature 
death, especially where the disease is not diagnosed or is poorly controlled (International 
Diabetes Federation 2006). Short-term health complications may include diabetic 
ketoacidosis, hypoglycaemia, increased susceptibility to infections and reduced ability to 
heal. Over the longer term, diabetes may progress to a range of health complications 
including heart disease, stroke, kidney disease, blindness and nerve damage, which may 
lead to lower limb amputation (AIHW 2009). Many studies around the world have shown an 
increase in the incidence of both type 1 and type 2 diabetes. Although the reasons behind 
increases in type 1 diabetes, which is an unpreventable autoimmune disease, remain largely 
unknown, the rise in type 2 diabetes has been linked to increasing obesity, the ageing 
population, dietary changes and sedentary lifestyles (Baker IDI Heart and Diabetes Institute 
2012). The key modifiable risk factors for diabetes include physical inactivity, unhealthy diet, 
obesity, tobacco smoking, high blood pressure and high blood lipids.  
Monitoring diabetes is essential to improve capacity to plan preventive and treatment 
services, to target priority population groups, to track the impact of environmental change 
and of prevention and control strategies, and to make decisions for cost-effective allocation 
of resources (AIHW 2006). The findings in this report provide important information on the 
incidence of insulin-treated diabetes to researchers, health professionals, service planners 
and policy makers to assist with this monitoring. 
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Box 1.1: Diabetes and insulin use 
Diabetes occurs when the body is no longer able to produce enough insulin—a hormone 
made by cells in the pancreas—or use it properly. When people eat, insulin is released into 
the blood stream where it helps to move glucose from food into cells where it can be used as 
a source of energy. 
Insulin injections are required when the body produces little or no insulin, as with type 1 
diabetes. Insulin is also required for many people with type 2 diabetes when other diabetes 
medications, together with healthy eating and regular physical activity, are not enough to 
control blood glucose levels.  
All people with type 1 diabetes use insulin and, in Australia, around 20% of those with type 
2 diabetes use it to control blood glucose levels (AIHW 2006; Davis et al. 2012). The 
proportion of women with gestational diabetes who are treated with insulin is around 32% 
(AIHW 2008). 
 
The aim of this report is to present the latest available data on new cases (incidence) of 
insulin-treated diabetes in Australia, using the National (insulin-treated) Diabetes Register 
(NDR) (see Box 1.2). The NDR, established in 1999, aims to record all new cases of people 
who use insulin to treat diabetes, including type 1, type 2, gestational and other forms of 
diabetes. Most people with type 1 diabetes in Australia are captured by the NDR because, 
almost without exception, people with type 1 diabetes require insulin for survival. However, 
only a proportion of people with type 2, gestational and other types of diabetes require 
insulin treatment; those who do not are excluded from the NDR. 
This report examines the incidence of each type of insulin-treated diabetes―type 1, type 2 
and gestational diabetes―by age and sex, geographic location and variations in population 
groups, such as remoteness, socioeconomic status and Aboriginal and Torres Strait Islander 
status. Trend information is presented for type 1 diabetes as these data are considered 
reliable and robust over time, given that almost all people with type 1 diabetes use insulin to 
manage their condition. For insulin-treated type 2 diabetes and gestational diabetes trend 
information has not been presented due to changes in treatment regimens for type 2 diabetes 
and screening of gestational diabetes over time. These factors are likely to influence trends, 
and make reporting of trends unreliable and difficult to interpret.   
There were around 53,500 people in Australia who began using insulin to treat their diabetes 
in 2011― 68% had type 2 diabetes, 12% had gestational diabetes, 4% had type 1 diabetes and 
1% had other forms of diabetes requiring insulin (for data relating to other types of diabetes 
requiring insulin refer to appendix tables A14 and A15). Diabetes type was unknown for 15% 
of people who began using insulin in 2011—see ‘Appendix B: Statistical notes and methods’ 
for further information. 
The Australian Institute of Health and Welfare (AIHW) has published several reports from 
earlier NDR data. However, results presented in this report cannot be compared with 
previous publications because the methods relating to the supply protocol and processing of 
the data have changed considerably.  
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Box 1.2: The National (insulin-treated) Diabetes Register 
The NDR is maintained by the AIHW under contract with the Department of Health. It was 
established to monitor the incidence and prevalence of insulin-treated diabetes in Australia 
(Colagiuri et al. 1998). The NDR is derived from two primary data sources: the National 
Diabetes Services Scheme and the Australasian Paediatric Endocrine Group.  
National Diabetes Services Scheme (NDSS) 
The NDSS, which was established in 1987 and is administered by Diabetes Australia, is an 
initiative of the Australian Government to subsidise the supply of diabetes–related products— 
such as pens and needles to administer insulin, blood glucose test strips and insulin pump 
consumables—to people who are registered with the scheme. 
Under a Memorandum of Understanding that specifies the data supply arrangements, Diabetes 
Australia provides the AIHW with data about the characteristics of people who are registered on 
the NDSS and products that they purchase, where these relate to insulin use. It is currently not 
possible to determine how many people with insulin-treated diabetes are not registered with the 
NDSS. However, the AIHW is progressing a project using Pharmaceutical Benefit Scheme data 
related to insulin claims, which may assist in furthering our knowledge in this area. 
Australasian Paediatric Endocrine Group (APEG) 
The APEG is a professional body that represents health professionals involved in the 
management and research of children and adolescents with disorders of the endocrine system 
including diabetes. 
The APEG maintains clinic-based state and territory diabetes registers. Paediatricians, 
physicians, paediatric endocrinologists, endocrinologists, diabetes educators and nurses report 
incident cases to these registers. Although each jurisdiction established its database 
independently, and at varying times since 1985, they have all prospectively ascertained all forms 
of insulin-treated diabetes in people aged under 15 at diagnosis and diagnosed from 1999 
onwards. 
The APEG supplies the AIHW with information from these registers. These data are supplied 
under a consultancy agreement between the two organisations, with the APEG being paid by 
the Department of Health to provide the data. 
National (insulin-treated) Diabetes Register (NDR) 
The NDR is compiled from the NDSS and APEG state and territory-based registers.  
In order to create the NDR, eligible NDSS registrants—those using insulin—need to be 
determined. It is likely that the methodology used to do this may overestimate the number of 
people who are using insulin. On the NDSS, there is no single variable indicating whether 
someone is using insulin to treat their diabetes, so a number of factors need to be considered in 
determining whether someone is using insulin.  
As the symptoms of type 1 and type 2 diabetes may be similar, particularly in young adults, the 
recorded diabetes type is not always reliable in the NDSS or APEG data collections. Therefore, 
as part of processing information from the data sources, the reported diabetes is checked against 
a set of test criteria and revised where necessary. The algorithm, defined in Box B3, assesses and 
re-classifies reported diabetes type for some registrants on the NDSS. For example, if reported 
diabetes is a NDSS record only, reclassification my occur through the algorithm (that is, if 
reported diabetes is type 1 diabetes and the time for first insulin use is more than 1 year later, 
the derived diabetes type would be type 2 diabetes). 
(continued) 
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Box 1.2: (continued) The National (insulin-treated) Diabetes Register 
All analysis in this report is based on the type of diabetes that has been derived by applying 
the test criteria and not that which was reported at registration. It should be noted that there 
were 7,956 people (15% of all insulin users) for whom diabetes type could not be derived, 
and these people, although insulin users, were not included in the analysis. 
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2 Type 1 diabetes 
Type 1 diabetes is an autoimmune disease that develops when the immune system destroys 
the insulin-producing cells of the pancreas. The subsequent absence of insulin means glucose 
cannot be transported into the cells, where it is used for energy, and blood glucose levels 
rise, which requires replacement insulin to be administered. The exact cause of type 1 
diabetes is unknown, although it is believed to be an interaction of genetic predisposition 
and environmental factors. 
Although type 1 diabetes can occur at any age, it mainly develops during childhood and 
adolescence (Craig et al. 2011). Currently, once a person is diagnosed, they will require 
insulin treatment every day throughout their life. The only exception to this is where a 
person has had a pancreatic transplant, but this is relatively rare.  
This chapter presents the incidence of type 1 diabetes in Australia in 2011 and for the period 
2000–11. Because all people with type 1 diabetes use insulin as the mainstay of treatment, 
they are well represented on the NDR, as this requirement acts as a driver for registration 
with the NDSS to obtain subsidised diabetes-related products essential for administering 
insulin. Additionally, for those aged under 15, two data sources are used to ascertain 
incidence (that is, newly diagnosed cases), resulting in a coverage rate of 99% (see ‘Appendix 
B: Statistical notes and methods’ for further information). 
How many people were diagnosed with type 1 
diabetes in 2011? 
In 2011, there were 2,367 new cases of people with type 1 diabetes in Australia; this 
represents 11 cases per 100,000 population (Table A1).  
Age and sex 
The incidence of type 1 diabetes was higher in males than in females—13 in every 100,000 
males compared with 8 per 100,000 females (Table A1).  
Females were more likely to be diagnosed at a younger age than males—the mean age at 
diagnosis for females was 21 compared with 25 for males. However, in younger age groups 
there was no difference in the average age at diagnosis: for those under 15, the mean age was 
8 for both males and females.  
About half of those diagnosed with type 1 diabetes in 2011 were aged 18 or under, with the 
peak age of diagnosis at age 10–14. In this age group, incidence was 32 per 100,000 
population, 3 times the rate at 30–34 (10 per 100,000) and 5 times the rate at age 40–44 (6 per 
100,000 population) (Figure 2.1; Table A1). 
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Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Some of those diagnosed in older age groups may have had late-onset autoimmune diabetes of adults: a condition that requires 
insulin relatively soon after diagnosis, but not necessarily immediately (Diabetes Australia 2012). If these people were reported as 
having type 1 diabetes and began using insulin within the first year of diagnosis, their diabetes type remained for this analysis as  
type 1.  
Source: AIHW analysis of the NDR 2011 (Table A1). 
Figure 2.1: Incidence of type 1 diabetes by age at diagnosis and sex, Australia, 2011 
State and territory 
For most states and territories, the incidence of type 1 diabetes did not vary considerably, 
except for the Northern Territory (NT) where the incidence rate at 8 per 100,000 was 
comparatively low (Figure 2.2; Table A2). For all Australians, 11 in every 100,000 were 
diagnosed with type 1 diabetes in 2011, and the incidence rate (excluding the NT) ranged 
from 10 in every 100,000 people in both New South Wales (NSW) and South Australia (SA) 
to 13 per 100,000 in Western Australia (WA). 
The lower incidence of type 1 diabetes in the NT may have been due to the high proportion 
of Aboriginal and Torres Strait Islander people living there, who not only have a lower 
incidence of type 1 diabetes than non-Indigenous people (Maple-Brown et al. 2008) but are 
possibly less likely to register with the NDSS (see ‘Appendix B: Statistical notes and 
methods’ for information). 
Apart from the NT, the incidence rate was higher for males than for females across Australia 
(Figure 2.2). In the NT, the pattern was reversed in 2011 with a slightly higher incidence rate 
for females than males (9 compared with 7 per 100,000, respectively); however for the  
2000–11 period as a whole, incidence rates were higher for males than females in the NT, 
reflecting the pattern seen across the other states and territories (Table A3). 
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Source: AIHW analysis of the NDR 2011 (Table A3). 
Figure 2.2: Incidence of type 1 diabetes by state or territory of usual residence and sex, Australia, 
2011 
Does type 1 diabetes vary across population 
groups? 
Remoteness 
In 2011, the incidence of type 1 diabetes was slightly lower in Remote and very remote areas 
than in Major cities and regional areas ― 8 per 100,000 people in Remote and very remote areas 
compared with respectively 10, 12 and 11 per 100,000 people in Major cities, Inner regional and 
Outer regional areas (Figure 2.3; Table A2). 
Socioeconomic status 
In Australia, the incidence of type 1 diabetes in 2011 did not vary by SES, with incidence 
remaining around 10 to 11 new cases per 100,000 people across all SES groups (Figure 2.3; 
Table A2). 
Aboriginal and/or Torres Strait Islander status 
In 2011, there were 62 Aboriginal and Torres Strait Islander people diagnosed with type 
1 diabetes (Table A2). 
In 2006–2011, there were 294 Indigenous Australians diagnosed with type 1 diabetes: an 
average of 49 cases per year (Table A4). After adjusting for age and sex, Indigenous 
Australians were less likely to be diagnosed with type 1 diabetes than non-Indigenous 
Australians (incidence rate of 7 per 100,000 compared with 10 per 100,000) (Figure 2.3; 
Table A5). 
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Notes 
1. Interpreting results for Indigenous status needs to consider that in 24% of cases no status was stated. The Indigenous results relate to 
the period 2006-2011.  
2. Indigenous and non-Indigenous data refer to combined data for 2006-2011 and rates have been age and sex standardised to the 2001 
Australian population. 
Source: AIHW analysis of the NDR 2011 (Table A2; Table A5). 
Figure 2.3: Incidence of type 1 diabetes by population groups, Australia, 2011 
Are incidence rates changing over time? 
Between 2000 and 2011, there were on average around 2,200 new cases of type 1 diabetes 
each year, equating to around 6 new cases per day over this period (Table A6). 
The incidence of new cases of type 1 diabetes did not change significantly from 2000 to 2011. 
After taking into account differences in the age and sex structure, the incidence of type 1 
diabetes fluctuated between 10 and 12 cases per 100,000 population each year. Similarly, 
there were no significant differences in the trends for males or females or across age groups 
over this period. The numbers of new cases for females ranged from 8 to 10 cases per 100,000 
each year and for males, 11 to 14 (Table A7; Table A8). 
These findings were also confirmed with joinpoint regression analysis, which showed that 
the slope of the fitted trend line was not statistically significantly different from zero (Figure 
2.4). Joinpoint is used to assist in determining a linear trend, or a series of linear trends, by 
fitting lines that most closely represent the pattern of data points. The slope of the line 
provides a measure of the magnitude of the change in incidence over time. 
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Notes 
1. Diagnosis year is determined by year at first insulin use. 
2. Age- and sex-standardised to the 2001 Australian population. 
3. Modelled rate is determined using joinpoint analysis.  
Source: AIHW analysis of the NDR 2011 (Table A9). 
Figure 2.4: Trend in the incidence of type 1 diabetes by year of diagnosis, observed and modelled 
rates, Australia, 2000–11 
How does Australia compare on rates of type 1 
diabetes? 
Because diagnosis is usually made in childhood, much of the international literature on the 
incidence of type 1 diabetes focuses on young people. Of the 30 Organisation for Economic 
Co-operation and Development (OECD) countries for which comparable data were 
available, Finland had the highest rate of incidence of type 1 diabetes among children aged 
0–14 (58 per 100,000), while Korea had the lowest rate (1 per 100,00) (OECD 2013). The cause 
of the high rates of type 1 diabetes in Finland is attributed to a combination of genetic and 
lifestyle factors (Myers & Zimmet 2008). Australia’s incidence rate of type 1 diabetes of 23 
per 100,000 population aged 0–14 was high compared with other OECD countries: 6th 
highest and above the OECD average (17 per 100,000) for the 30 countries which data is 
available (Figure 2.5). 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Year of diagnosis
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Modelled rate
Rate
Number per 100,000 population
 10 Incidence of insulin-treated diabetes in Australia 2000–2011 
 
Notes 
1. Incidence for Australia is the estimate provided by the OECD (23 per 100,000). This is slightly lower than the rate from the NDR (24 
per 100,000) 
2. OECD estimates are based on estimates from the International Diabetes Federation for 2011; the data were age standardised to the 
World Standard Population. 
Source: OECD 2013. 
Figure 2.5: Estimates of the incidence rate of type 1 diabetes for those aged 0–14, selected countries, 
2011 
 
In recent years, an increase in the incidence of type 1 diabetes has been observed in many 
countries, at a rate of around 3% annually on average (Moltchanova et al. 2009). However, 
this increase was not evident in the trend analysis relating to Australia from 2000 to 2011 
presented in this chapter.  
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3 Insulin-treated type 2 diabetes 
Type 2 diabetes is the most common form of diabetes. It occurs when the body becomes 
resistant to the insulin being produced by the pancreas and the amount produced is 
inadequate to meet the body’s needs. Insulin is often used in the treatment of type 2 diabetes, 
but not in all cases. In addition to their insulin resistance, whether or not a person with type 
2 diabetes requires insulin is often dependent on blood glucose control, comorbidities, 
duration of the disease, age at onset; and other risk factors that influence the development of 
the disease, such as age, family history and ethnic background (Shaw & Chisholm 2003). 
Type 2 diabetes is largely preventable: up to 60% of cases can potentially be avoided by 
maintaining a healthy lifestyle (Diabetes Australia 2013a). However, rates of type 2 diabetes 
have doubled over the last 2 decades, paralleling increases in obesity (Fox et al. 2006; Holden 
et al. 2013; Tseng et al. 2006). Although type 2 diabetes is most commonly diagnosed in 
adulthood, in recent years there has been an increasing emergence of type 2 diabetes in 
younger age groups (Lammi et al. 2007; Taplin et al. 2005; Tseng et al. 2006). The AIHW have 
recently released a report Type 2 diabetes in Australia’s children and young people: a working 
paper, which provides some preliminary work in this area. 
This chapter covers only cases of type 2 diabetes that require insulin treatment, because the 
NDR captures people who use insulin to treat their diabetes. It is important to note that this 
does not capture all cases of type 2 diabetes, because many people with type 2 diabetes 
manage their condition by lifestyle modification or other medications. 
How many people with type 2 diabetes started using 
insulin in 2011? 
In 2011 in Australia, 36,263 people with type 2 diabetes began to use insulin to treat their 
condition; this represents 163 cases per 100,000 people (Table A10). 
Age and sex 
Rates of insulin-treated type 2 diabetes were higher among males than females at 185 per 
100,000 population compared with 140 per 100,000, respectively (Table A10).  
The incidence of insulin-treated type 2 diabetes increased rapidly with age from a rate of 
around 100 people per 100,000 population among those aged 40–44 to over 550 per 100,000 
for those aged 70–74. Similar patterns were seen for males and females, although rates 
among females were lower and did not increase as rapidly as for males (Figure 3.1). 
On average, both males and females were diagnosed with type 2 diabetes at a similar age 
and began to use insulin about 10 years after diagnosis. For males, the average age of 
diagnosis was 52 and the average age of first insulin use was 62. For females, the respective 
ages were 51 and 61. 
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Source: AIHW analysis of the NDR 2011 (Table A10). 
Figure 3.1: Incidence of insulin-treated type 2 diabetes by age at first insulin use and sex, Australia, 
2011 
State and territory 
In 2011, the incidence of insulin-treated type 2 diabetes varied by state and territory of 
residence, ranging from 200 cases per 100,000 population in NSW to 92 per 100,000 in the 
Australian Capital Territory (ACT) (Figure 3.2; Table A11). 
 
Source: AIHW analysis of the NDR 2011 (Table A11). 
Figure 3.2: Incidence of insulin-treated type 2 diabetes by state or territory of usual residence and 
sex, Australia, 2011 
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Does insulin-treated type 2 diabetes vary across 
population groups? 
This section examines how insulin use for type 2 diabetes varies across population groups 
that are often associated with differing levels of health. 
Remoteness 
The incidence of insulin-treated type 2 diabetes was lower in Major cities (150 per 100,000) 
than in Remote and very remote areas (165 per 100,000). Rates were higher in both Inner regional 
and Outer regional areas (191 and 193 per 100,000 population, respectively) (Figure 3.3; 
Table A11). 
 
 
Notes 
1. Interpreting results for Indigenous status needs to consider that in 54% of cases no status was recorded or the registration occurred 
before 2005. 
2. Indigenous and non-Indigenous data refer to combined data for 2006–11 and rates have been age and sex standardised to the 2001 
Australian population. 
Source: AIHW analysis of the NDR 2011 (Table A11). 
Figure 3.3: Incidence of insulin-treated type 2 diabetes by population groups, Australia, 2011 
Socioeconomic status 
The incidence of insulin-treated type 2 diabetes increased with increasing socioeconomic 
disadvantage. Rates of type 2 diabetes were twice as high in areas of lowest socioeconomic 
status compared with highest SES areas (233 compared with 98 per 100,000 population, 
respectively). This largely reflects the higher prevalence of type 2 diabetes in lower SES areas 
than in higher SES areas (Figure 3.3; Table A11). 
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Aboriginal and/or Torres Strait Islander status 
There were 656 Aboriginal and Torres Strait Islander people who began using insulin to treat 
their type 2 diabetes in 2011 (Table A11). The incidence of insulin-treated diabetes was 
almost four times as high among Indigenous Australians compared with non-Indigenous 
Australians (134 compared with 36 per 100,000 population) (Figure 3.3; Table A11).  
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4 Insulin-treated gestational diabetes 
Gestational diabetes (GDM), which occurs in about 1 in 20 pregnancies (AIHW 2010), 
generally develops in the second or third trimester. In Australia, women are routinely 
screened for GDM at about 24–28 weeks gestation (Nankervis et al. 2013). Women at highest 
risk of GDM include those who have had gestational diabetes previously, are from certain 
ethnic groups, are aged over 30, have a family history of diabetes, or commenced pregnancy 
being overweight or obese (AIHW 2010).  
Complications from GDM can result for both the mother and baby. Complications for the 
mother involve higher risks of pregnancy-induced hypertension and pre-eclampsia, induced 
labour and operative delivery. Complications for the baby include increased fetal growth 
and perinatal morbidity, respiratory distress syndrome, jaundice and shoulder dystocia. 
GDM usually abates after pregnancy, but increases the risk that both the mother and the 
baby may develop type 2 diabetes later in life; this is more so where the mother has used 
insulin during pregnancy (Lee et al. 2007). 
Some women can manage their GDM by changes to diet and exercise, but many will require 
medication, including insulin treatment. The proportion of GDM cases requiring insulin in 
Australia is about 32% (AIHW 2008), although this varies by factors such as ethnicity and 
diet, and can range from less than 30% to over 60% (Moses et al. 2009; Wong 2012; Wong & 
Jalaludin 2011).  
This chapter examines the incidence of insulin-treated GDM in 2011, but some caution needs 
to be exercised when interpreting these figures. The rates refer to the number per 100,000 of 
the female population aged 15–49, not to the population at risk: those who are pregnant. 
Additionally, as the propensity to be pregnant varies with age, rates could not be compared 
directly across age groups. 
How many women had insulin-treated gestational 
diabetes in 2011? 
In 2011 in Australia, 6,362 women aged 15–49, representing 117 per 100,000 women aged 15–
49, began using insulin to treat their gestational diabetes. The mean age was 33 (Table A12). 
State and territory 
In 2011, the incidence of insulin-treated gestational diabetes varied by state and territory of 
residence, ranging from 178 per 100,000 women aged 15–49 in NSW to 43 per 100,000 in WA 
(Figure 4.1; Table A13).  
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Note: Population refers to all females aged 15–49, not only those who were pregnant. 
Source: AIHW analysis of NDR 2011 (Table A13). 
Figure 4.1: Incidence of insulin-treated gestational diabetes for women aged 15–49 by state or 
territory of usual residence, Australia, 2011 
 
Does insulin–treated gestational diabetes vary 
across population groups? 
This section examines how insulin use for gestational diabetes varies across population 
groups that are often associated with differing levels of health.  
Remoteness 
Women aged 15-49 living in Major cities were 2.5 times as likely to be using insulin to treat 
their gestational diabetes than those in living in Remote and very remote areas of Australia 
(incidence rate of 129 per 100,000 compared with 50 per 100,000 women, respectively) 
(Figure 4.2; Table A13). 
This difference may be due to differing levels of diagnosis and/or access to services and GPs 
or specialist health professionals, such as endocrinologists or obstetricians, for women living 
in urban areas compared with those living in more remote areas of Australia. 
Socioeconomic status 
The incidence of insulin-treated gestational diabetes increased with increasing 
socioeconomic disadvantage. Women living in areas of lowest SES were almost twice as 
likely to be using insulin to treat their gestational diabetes as those living in the highest SES 
areas (152 compared with 84 per 100,000 population, respectively). This partly reflects the 
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higher prevalence of gestational diabetes in lower SES areas compared with higher SES areas 
(Figure 4.2; Table A13). 
Aboriginal and/or Torres Strait Islander status 
There were 118 Indigenous women who commenced insulin use to treat gestational diabetes 
in 2011 (Table A13). Age– and sex–standardised incidence rates were similar for Indigenous 
and non-Indigenous Australians at 60 and 59 per 100,000, respectively (Figure 4.2).  
 
 
Notes 
1. Population refers to all females aged 15–49, not only those who were pregnant. 
2. Interpreting results for Indigenous status needs to consider that in 26% of cases no status was recorded or the registration occurred 
before 2005. 
3. Indigenous and non-Indigenous data refer to combined data for 2006–11 and rates have been age and sex standardised to the 2001 
Australian population. 
Source: AIHW analysis of NDR 2011. 
Figure 4.2: Incidence of insulin-treated gestational diabetes for women aged 15–49 by population 
groups, Australia, 2011 
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Appendix A Detailed tables 
Type 1 diabetes 
Table A1: Incidence of type 1 diabetes by age at diagnosis and 
sex, Australia, 2011
 
Number  Age-specific rate 
Males Females Persons  Males Females Persons 
0–4 123 97 220  16.4 13.7 15.1 
5–9 168 157 325  23.8 23.5 23.7 
10–14 229 209 438  32.3 31.0 31.7 
Subtotal (0–14) 520 463 983  24.1 22.6 23.3 
15–19 160 97 257  21.4 13.7 17.6 
20–24 128 84 212  15.5 10.7 13.2 
25–29 139 69 208  16.5 8.4 12.6 
30–34 115 39 154  15.0 5.1 10.0 
35–39 93 34 127  11.9 4.3 8.1 
40–44 62 29 91  7.9 3.6 5.8 
45–49 44 24 68  5.7 3.1 4.4 
50–54 45 30 75  6.1 4.0 5.0 
55–59 36 15 51  5.5 2.2 3.8 
60–64 23 14 37  3.7 2.2 3.0 
65–69 22 14 36  4.6 2.9 3.8 
70–74 21 6 27  6.0 1.6 3.8 
75–79 7 5 12  2.7 1.7 2.2 
80–84 10 5 15  5.3 2.0 3.4 
85+ 8 6 14  5.8 2.3 3.5 
Subtotal (15+) 913 471 1,384  10.2 5.1 7.6 
Total 1,433 934 2,367  12.9 8.3 10.6 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
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Table A2: Incidence of type 1 diabetes by sex and population characteristics, 
Australia, 2011
 
Number  Crude rate  
Males Females Persons  Males Females Persons 
State and territory(a)        
New South Wales 410 293 703  11.5 8.1 9.7 
Victoria 367 219 586  13.4 7.8 10.6 
Queensland 297 197 494  13.3 8.8 11.0 
Western Australia 185 117 302  15.6 10.0 12.8 
South Australia 110 57 167  13.6 6.9 10.2 
Tasmania 31 23 54  12.2 9.0 10.6 
Australian Capital Territory 25 18 43  13.7 9.7 11.7 
Northern Territory 8 10 18  6.6 9.1 7.8 
Remoteness(b)        
Major cities 960 634 1,594  12.4 8.0 10.2 
Inner regional 297 199 496  14.6 9.7 12.1 
Outer regional 149 81 230  14.5 8.1 11.3 
Remote/Very remote 24 15 39  8.6 6.3 7.7 
Socioeconomic status(c)        
Group 1 (lowest SES) 300 183 483  13.4 8.2 10.8 
Group 2 276 186 462  12.4 8.3 10.4 
Group 3 303 189 492  13.7 8.4 11.0 
Group 4 280 177 457  12.7 7.9 10.3 
Group 5 (highest SES) 269 194 463  12.1 8.5 10.3 
Indigenous status        
Indigenous 37 25 62  12.9 8.7 10.8 
Non-Indigenous 1,033 707 1,740  9.6 6.5 8.0 
Not stated 363 202 565  — — — 
Australia(d) 1,433 934 2,367  12.9 8.3 10.6 
(a) State or territory of current usual residence. 
(b) Remoteness is classified according to the Australian Statistical Geography Standard (ASGS) 2011 Remoteness Areas structure based on 
postcode of current usual residence. 
(c) Socioeconomic status is classified into population-based quintiles according to the Index of Relative Socio-Economic Disadvantage (IRSD) 
based on postcode of current usual residence. 
(d) Includes people for whom certain population characteristics could not be derived, so subcomponents may not add to Australian total. 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
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Table A3: Incidence of type 1 diabetes by state or territory of usual residence and sex, Australia, 
2011 and 2000–11 
 2011  2000–11 
 Males Females Persons  Males Females Persons 
 Number 
Crude 
rate Number 
Crude 
rate Number 
Crude 
rate  Number 
Crude 
rate Number 
Crude 
rate Number 
Crude 
rate 
NSW 410 11.5 293 8.1 703 9.7  4,894 12.0 3,465 8.4 8,359 10.2 
Vic 367 13.4 219 7.8 586 10.6  3,820 12.6 2,831 9.1 6,651 10.8 
Qld 297 13.3 197 8.8 494 11.0  3,173 13.1 2,220 9.1 5,393 11.1 
WA 185 15.6 117 10.0 302 12.8  1,698 13.6 1,103 8.9 2,801 11.2 
SA 110 13.6 57 6.9 167 10.2  1,180 12.7 817 8.6 1,997 10.6 
Tas 31 12.2 23 9.0 54 10.6  430 14.8 315 10.6 745 12.7 
ACT 25 13.7 18 9.7 43 11.7  263 13.1 193 9.4 456 11.3 
NT 8 6.6 10 9.1 18 7.8  102 7.7 70 5.8 172 6.8 
Australia 1,433 12.9 934 8.3 2,367 10.6  15,561 12.6 11,014 8.8 26,575 10.7 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
 
 
Table A4: Incidence of type 1 diabetes by Indigenous status and year of diagnosis, Australia,  
2005–2011(a) 
 
Indigenous  Non-Indigenous  Not stated 
Total Number %  Number %  Number % 
2005 52 2.7  1,734 90.0  141 7.3 1,927 
2006 41 1.9  1,860 88.2  208 9.9 2,109 
2007 58 2.4  2,140 89.0  207 8.6 2,405 
2008 46 1.9  2,196 93.0  119 5.0 2,361 
2009 37 1.7  1,918 88.7  208 9.6 2,163 
2010 50 2.1  2,018 86.3  271 11.6 2,339 
2011 62 2.6  1,740 73.5  565 23.9 2,367 
2005–2011 346 2.2  13,606 86.8  1,719 11.0 15,671 
(a) Analysis excludes 26 NDSS registrations before 2005 due to data quality issues. 
Note: Year of first insulin use is a proxy for year of diagnosis. 
Source: AIHW analysis of the NDR 2011. 
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Table A5: Incidence of type 1 diabetes by Indigenous status and  
year of diagnosis, Australia, 2005–2011(a) 
 
Indigenous 
Non-
Indigenous All Australians 
Age- and sex-standardised rate 
2006 6.0 9.6 10.5 
2007 10.1 10.9 11.8 
2008 7.0 11.0 11.4 
2009 4.7 9.5 10.3 
2010 8.4 10.0 11.1 
2011 8.4 8.5 11.1 
2006–2011 7.4 9.9 12.6 
(a) Analysis excludes 10 NDSS registrations prior to 2005 due to data quality issues. 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Age- and sex-standardised to the 2001 Australian population. 
3. Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
 
 
Table A6: Incidence of type 1 diabetes by year of diagnosis and sex, Australia, 2000–11 
 
Males Females Persons 
Number % Rate Number % Rate Number Rate 
2000 1,261 57.7 13.2 925 42.3 9.6 2,186 11.4 
2001 1,308 57.1 13.6 982 42.9 10.0 2,290 11.8 
2002 1,147 57.5 11.8 849 42.5 8.6 1,996 10.2 
2003 1,301 56.8 13.3 987 43.2 9.9 2,288 11.6 
2004 1,247 58.8 12.7 872 41.2 8.7 2,119 10.7 
2005 1,110 57.1 11.2 833 42.9 8.3 1,943 9.7 
2006 1,259 59.6 12.5 853 40.4 8.4 2,112 10.5 
2007 1,451 60.2 14.2 959 39.8 9.4 2,410 11.8 
2008 1,389 58.8 13.5 974 41.2 9.4 2,363 11.4 
2009 1,293 59.7 12.4 872 40.3 8.3 2,165 10.3 
2010 1,364 58.3 12.9 975 41.7 9.2 2,339 11.1 
2011 1,433 60.6 13.4 934 39.4 8.7 2,367 11.1 
2000–11 15,561 58.6 12.9 11,014 41.4 9.0 26,578 10.9 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Age- and sex-standardised to the 2001 Australian population. 
3. Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
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Table A7: Incidence of type 1 diabetes by year of diagnosis, by sex and age at first insulin use, 
Australia, 2000–11
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2000–11(a) 
Age- and sex-standardised rate (number per 100,000 population) 
Males              
0–19 20.1 21.7 21.8 23.9 24.3 22.0 23.5 24.9 24.1 23.0 23.6 23.6 23.0 
20–29 14.9 15.9 13.4 17.5 14.7 13.4 14.1 18.6 16.0 14.8 13.3 16.1 15.2 
30–39 12.9 12.9 10.0 11.7 12.1 10.0 11.2 13.7 13.4 11.0 12.6 13.4 12.1 
40+ 8.2 7.5 5.2 5.4 4.4 3.6 5.1 5.8 5.5 4.9 5.7 5.7 5.5 
Total 13.2 13.6 11.8 13.3 12.7 11.2 12.5 14.2 13.5 12.4 12.9 13.4 12.9 
Females              
0–19 19.4 20.0 20.6 23.4 21.2 20.7 19.7 21.6 22.6 18.9 22.4 20.6 20.9 
20–29 9.5 9.6 8.4 9.9 8.1 7.9 7.8 8.6 9.8 9.3 8.5 9.5 8.9 
30–39 6.3 6.3 4.2 6.7 6.2 4.8 6.5 5.9 5.2 5.6 5.4 4.7 5.6 
40+ 4.8 5.5 3.0 3.0 2.4 2.2 2.5 3.5 2.8 2.6 2.9 2.8 3.1 
Total 9.6 10.0 8.6 9.9 8.7 8.3 8.4 9.4 9.4 8.3 9.2 8.7 9.0 
Persons              
0–19 19.7 20.9 21.3 23.6 22.8 21.3 21.7 23.3 23.4 21.0 23.0 22.1 22.0 
20–29 12.2 12.8 10.9 13.8 11.4 10.7 11.0 13.7 12.9 12.1 10.9 12.8 12.1 
30–39 9.6 9.6 7.1 9.2 9.1 7.4 8.8 9.8 9.2 8.3 9.0 9.0 8.8 
40+ 6.4 6.5 4.1 4.1 3.3 2.9 3.7 4.6 4.1 3.7 4.3 4.2 4.3 
Total 11.4 11.8 10.2 11.6 10.7 9.7 10.5 11.8 11.4 10.3 11.1 11.1 10.9 
(a) The rate for 2000–11 is the average annual rate for the 12 years. 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Age- and sex-standardised to the 2001 Australian population. 
Source: AIHW analysis of the NDR 2011.  
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Table A8: Incidence of type 1 diabetes by year of diagnosis, by sex and age at first insulin use, 
Australia, 2000–11
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2000–11(a) 
Age- and sex-standardised rate (number per 100,000 population) 
Males              
0–14 21.2 23.3 23.1 25.2 25.9 23.2 24.4 26.5 25.2 24.9 24.2 24.3 24.3 
15+ 11.1 11.0 8.8 10.1 9.1 7.9 9.3 10.9 10.3 9.0 9.9 10.5 9.8 
Total 13.2 13.6 11.8 13.3 12.7 11.2 12.5 14.2 13.5 12.4 12.9 13.4 12.9 
Females              
0–14 20.8 21.5 23.8 26.2 24.4 23.4 22.1 24.2 25.0 21.1 25.3 22.9 23.4 
15+ 6.8 7.2 4.9 5.9 4.9 4.6 5.0 5.7 5.5 5.1 5.3 5.2 5.5 
Total 9.6 10.0 8.6 9.9 8.7 8.3 8.4 9.4 9.4 8.3 9.2 8.7 9.0 
Persons              
0–14 21.0 22.4 23.4 25.7 25.2 23.3 23.3 25.3 25.1 23.0 24.7 23.6 23.8 
15+ 8.9 9.0 6.8 8.0 7.0 6.2 7.1 8.3 7.9 7.0 7.6 7.8 7.6 
Total 11.4 11.8 10.2 11.6 10.7 9.7 10.5 11.8 11.4 10.3 11.1 11.1 10.9 
(a) The rate for 2000–11 is the average annual rate for the 12 years. 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Age- and sex-standardised to the 2001 Australian population. 
Source: AIHW analysis of the NDR 2011. 
 
 
Table A9: Incidence of type 1 diabetes by year of diagnosis, observed and modelled rates, 
Australia, 2000–11
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age- and sex-standardised rate (number per 100,000 population) 
All ages             
Rate 11.4 11.8 10.2 11.6 10.7 9.7 10.5 11.8 11.4 10.3 11.1 11.1 
Modelled 
rate 11.1 11.1 11.0 11.0 11.0 11.0 11.0 11.0 10.9 10.9 10.9 10.9 
Aged 40 and over 
Rate 6.4 6.5 4.1 4.1 3.3 2.9 3.7 4.6 4.1 3.7 4.3 4.2 
Modelled 
rate 6.6 5.7 4.9 4.1 3.2 3.4 3.6 3.7 3.9 4.1 4.3 4.4 
Notes 
1. Year of first insulin use is a proxy for year of diagnosis. 
2. Age- and sex-standardised to the 2001 Australian population. 
Source: AIHW analysis of the NDR 2011. 
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Insulin-treated type 2 diabetes 
Table A10: Incidence of insulin-treated type 2 diabetes by sex and  
age at first insulin use, Australia, 2011
 
Number  Age-specific rate  
Males Females Persons  Males Females Persons 
0–14 6 9 15  0.3 0.4 0.4 
15–19 24 32 56  3.2 4.5 3.8 
20–24 61 95 156  7.4 12.1 9.7 
25–29 149 264 413  17.7 32.3 24.9 
30–34 342 431 773  44.5 56.2 50.3 
35–39 560 613 1,173  71.6 77.4 74.5 
40–44 909 795 1,704  116.1 99.4 107.7 
45–49 1,546 1,126 2,672  200.8 144.0 172.2 
50–54 2,184 1,523 3,707  295.5 201.8 248.1 
55–59 2,782 1,910 4,692  422.0 283.4 351.9 
60–64 3,336 2,143 5,479  542.1 343.1 441.9 
65–69 2,949 1,916 4,865  622.9 400.0 510.8 
70–74 2,314 1,674 3,988  662.2 452.6 554.5 
75–79 1,758 1,330 3,088  681.2 443.8 553.6 
80–84 1,062 1,063 2,125  557.6 419.6 478.8 
85+ 573 784 1,357  412.4 296.6 336.5 
Total 20,555 15,708 36,263  185.2 139.9 162.4 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
 
  
  Incidence of insulin-treated diabetes in Australia 2000–2011 25 
Table A11: Incidence of insulin-treated type 2 diabetes by sex  
and population characteristics, Australia, 2011
 
Number  Crude rate  
Males Females Persons  Males Females Persons 
State and territory(a)        
New South Wales 8,413 6,324 14,737  235.1 174.1 204.4 
Victoria 4,534 3,492 8,026  165.7 124.8 145.0 
Queensland 3,761 2,836 6,597  168.6 126.4 147.4 
Western Australia 1,552 1,277 2,829  131.2 109.2 120.3 
South Australia 1,494 1,122 2,616  184.4 135.5 159.7 
Tasmania 465 343 808  182.8 133.6 158.1 
Australian Capital Territory 185 154 339  101.2 83.2 92.2 
Northern Territory 151 160 311  124.3 145.7 134.4 
Remoteness(b)        
Major cities 13,372 10,178 23,550  172.5 128.5 150.3 
Inner regional 4,486 3,334 7,820  220.0 161.7 190.7 
Outer regional 2,204 1,709 3,913  214.2 170.3 192.5 
Remote/Very remote 427 428 855  152.6 178.4 164.5 
Socioeconomic status(c)        
Group 1 (lowest SES) 5,704 4,707 10,411  255.6 211.0 233.3 
Group 2 4,785 3,856 8,641  215.8 172.5 194.1 
Group 3 4,024 3,044 7,068  181.6 135.8 158.5 
Group 4 3,302 2,271 5,573  149.5 101.7 125.5 
Group 5 (highest SES) 2,662 1,758 4,420  120.0 77.2 98.3 
Indigenous status(d)        
Indigenous 302 354 656  105.3 122.6 114.0 
Non-Indigenous 7,605 5,458 13,063  70.3 49.9 60.1 
Not stated 2,189 1,513 3,702  — — — 
Australia(e) 20,555 15,708 36,263  185.2 139.9 162.4 
(a) State or territory of current usual residence. 
(b) Remoteness is classified according to the Australian Statistical Geography Standard (ASGS) 2011 Remoteness Areas structure based on 
postcode of current residence. 
(c) Socioeconomic status is classified into population-based quintiles according to the Index of Relative Socio-Economic Disadvantage (IRSD) 
based on postcode of current usual residence. 
(d) Indigenous status excludes 18,842 NDSS registrations before 2005 due to data quality issues. 
(e) Includes people for whom certain population characteristics could not be derived, so subcomponents may not add to Australian total. 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
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Insulin-treated gestational diabetes 
Table A12: Incidence of insulin-treated gestational 
diabetes among females aged 15–49 at first insulin use by 
age at first insulin use, Australia, 2011 
 Number Age-specific rate  
15–19 42 5.9 
20–24 359 45.6 
25–29 1,380 169.0 
30–34 2,195 286.3 
35–39 1,772 223.8 
40–44 566 70.8 
45–49 48 6.1 
Total 6,362 116.7 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011.  
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Table A13: Incidence of insulin-treated gestational diabetes among females aged 
15–49 at first insulin use by population characteristics, Australia, 2011
 Number Crude rate 
State and territory(a)   
New South Wales 3,097 178.1 
Victoria 1,533 111.2 
Queensland 917 83.5 
Western Australia 252 43.3 
South Australia 286 75.0 
Tasmania 129 113.4 
Australian Capital Territory 114 115.2 
Northern Territory 34 55.6 
Remoteness(b)   
Major cities 5,144 128.9 
Inner regional 819 91.7 
Outer regional 328 73.3 
Remote/Very remote 60 49.6 
Socioeconomic status(c)   
Group 1 (lowest SES) 1,552 151.6 
Group 2 1,312 125.1 
Group 3 1,366 123.9 
Group 4 1,157 102.5 
Group 5 (highest SES) 960 84.0 
Indigenous status(d)   
Indigenous 118 78.7 
Non-Indigenous 4,592 86.6 
Not stated 1,500 — 
Australia(e) 6,362 116.7 
(a) State or territory of current usual residence. 
(b) Remoteness is classified according to the Australian Statistical Geography Standard (ASGS) 2011 Remoteness Areas structure based on 
postcode of current usual residence. 
(c) Socioeconomic status is classified into population-based quintiles according to the Index of Relative Socio-Economic Disadvantage (IRSD) 
based on postcode of current usual residence. 
(d) Indigenous status excludes 152 NDSS registrations before 2005 due to data quality issues. 
(e) Includes people for whom certain population characteristics could not be derived, so subcomponents may not add to Australian total. 
Note: Rates are number per 100,000 population. 
Source: AIHW analysis of the NDR 2011. 
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Insulin-treated other diabetes types 
Table A14: Incidence of insulin-treated other diabetes types by sex and 
population characteristics, Australia, 2000–11 
  Number  
 Males Females Persons 
State and territory(a)    
New South Wales 484 353 837 
Victoria 376 295 671 
Queensland 255 221 476 
Western Australia 129 102 231 
South Australia 100 84 184 
Tasmania 35 35 70 
Australian Capital Territory 18 22 40 
Northern Territory 9 3 12 
Remoteness(b)    
Major cities 997 788 1,785 
Inner regional 255 214 469 
Outer regional 126 98 224 
Remote/Very remote 23 12 35 
Socioeconomic status(c)    
Group 1 (lowest SES) 317 238 555 
Group 2 285 226 511 
Group 3 276 223 499 
Group 4 266 223 489 
Group 5 (highest SES) 254 201 455 
Indigenous status(d)    
Indigenous 13 10 23 
Non-Indigenous 720 614 1,335 
Not stated 200 145 345 
Australia(e) 1,406 1,115 2,521 
(a) State or territory of current usual residence. 
(b) Remoteness is classified according to the Australian Statistical Geography Standard (ASGS) 2011 Remoteness Areas structure based on 
postcode of current usual residence. 
(c) Socioeconomic status is classified into population-based quintiles according to the Index of Relative Socio-Economic Disadvantage (IRSD) 
based on postcode of current usual residence. 
(d) Indigenous status excludes 818 NDSS registrations before 2005 due to data quality issues. 
(e) Includes people for whom certain population characteristics could not be derived, so subcomponents may not add to Australian total. 
Source: AIHW analysis of the NDR 2011. 
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Table A15: Incidence of insulin-treated other 
diabetes types by sex and year of first insulin use, 
Australia, 2000–11 
 
 Number  
Males Females Persons 
2000 20 46 96 
2001 78 47 125 
2002 70 43 113 
2003 78 58 136 
2004 81 64 145 
2005 89 75 164 
2006 112 89 202 
2007 107 77 184 
2008 120 93 213 
2009 116 112 228 
2010 199 163 362 
2011 305 248 553 
2000–11 1,406 1,115 2,521 
Source: AIHW analysis of the NDR 2011. 
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Appendix B: Statistical notes and methods 
Data sources: NDR 
The Data Quality Statement 
Information about limitations and issues regarding the NDR are found in the Data Quality 
Statement: National (insulin-treated) Diabetes Register 2011, which is located at: 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/563407>. 
Determining who is on the NDR 
In order to create the NDR, eligible NDSS registrants—those using insulin—need to be 
determined. It is likely that the method used to do this may have overestimated the number 
of people who are using insulin. On the NDSS, there is no single variable that indicates 
someone is using insulin to treat their diabetes, so inclusion on the NDR was determined by 
a number of factors as outlined in Box B1.  
The uncertainties mainly relate to the reliability of certification of insulin use by health 
professionals. The practicalities of registering with the NDSS, which require certification 
specifically for insulin use in addition to diabetes diagnosis, suggest that, in some instances, 
people diagnosed with type 2 or gestational diabetes are indicated as insulin-treated to cover 
the possibility that they may require insulin sometime in the future. This means that they can 
appear as an insulin user by the indications used to derive the NDR, but may in fact not 
actually have started using, insulin.  
Additionally, some people may choose not to comply with a health professional’s 
recommendations or, in the case of women with gestational diabetes, deliver their baby 
before any treatment is undertaken. 
 
Box B1: Factors indicating insulin use status 
From APEG: 
• All records from APEG were included, as all those supplied to the AIHW related to 
insulin use. 
From the NDSS, records were eligible for inclusion if: 
• the registrant had type 1 diabetes (this was determined by applying the algorithm that 
checked the diabetes type reported at registration—see ‘Diabetes type on the NDR’ and 
Box B3), or 
• there was evidence of the purchase of insulin-related products from NDSS sales 
information, or 
• the registrant had been certified as an insulin user by a doctor, endocrinologist or 
Credentialled Diabetes Educator on the NDSS registration/change in medication 
status form, or 
• a date of first insulin injection was recorded for the registrant. 
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On the NDR a person’s insulin use status was considered to be certain if their information 
was from APEG, or they had type 1 diabetes, or there was evidence they have purchased an 
insulin-related product through the NDSS. Uncertain insulin users were those who were 
certified by a doctor as using insulin or had a date of first injection recorded. 
For most years between 2000 and 2009, the insulin use status of around 70% of registrants is 
certain and in 2010 and 2011 the proportion of definite insulin users to all potential insulin 
users increased to 86% and 92%, respectively (Table B1). 
The AIHW is in the process of further verifying the insulin use of NDSS registrants, and has 
been granted ethical approval to access Pharmaceutical Benefit Scheme data relating to 
prescriptions for insulin. This project aims at improving the certainty of insulin use status, 
and consequently the understanding of the accuracy of the number of people on the NDR. 
Table B1: Insulin user status among NDR registrants by year of first insulin use, 2000–11 
Year of first insulin use 
Certain insulin users(a)  Uncertain insulin users(b) 
Total Number %  Number % 
2000 7,492 69.9  3,226 30.1 10,718 
2001 7,792 71.6  3,091 28.4 10,883 
2002 7,593 70.1  3,233 29.9 10,826 
2003 23,858 79.9  5,998 20.1 29,856 
2004 17,272 68.5  7,951 31.5 25,223 
2005 14,364 62.9  8,490 37.1 22,854 
2006 14,058 64.0  7,891 36.0 21,949 
2007 16,450 66.9  8,124 33.1 24,574 
2008 18,662 70.7  7,739 29.3 26,401 
2009 20,507 72.2  7,881 27.8 28,388 
2010 39,540 85.6  6,651 14.4 46,191 
2011 49,260 92.1  4,243 7.9 53,503 
2000–11 236,848 76.1  74,518 23.9 311,366 
(a) Certain insulin users have type 1 diabetes, evidence of insulin-related product purchase and/or record sourced from APEG. 
(b) Uncertain insulin users have an indication of insulin use, but not those described for certain insulin users above. 
Note: The increase in the number of people beginning to use insulin in 2003 and 2010 is partly related to structural changes to the NDSS 
database in 2002 and 2010 resulting in improved levels of checking and information retention. 
Source: AIHW analysis of the NDR 2011. 
Children with type 1 diabetes 
Information about children with type 1 diabetes is derived from two data sources—NDSS 
and APEG. The concordance between these and the estimated coverage of children with type 
1 diabetes is presented below. 
Concordance between the NDSS and APEG 
Table B2 shows the concordance between the NDSS and APEG data sets for new cases of 
type 1 diabetes in those diagnosed aged under 15. On average, from 2000 to 2011, about  
two-thirds of children with type 1 diabetes were registered with both the NDSS and APEG. 
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Table B2: NDR registrants with type 1 diabetes and aged under 15 at diagnosis by year of diagnosis 
and data source of record, 2000–11 
 
APEG only  APEG and NDSS  NDSS only 
Total NDR 
registrants Number %  Number %  Number % 
2000 15 1.8  565 67.8  253 30.4 833 
2001 17 1.9  639 71.5  238 26.6 894 
2002 16 1.7  682 72.8  239 25.5 937 
2003 14 1.4  749 72.7  267 25.9 1,030 
2004 14 1.4  690 68.2  308 30.4 1,012 
2005 14 1.5  638 68.0  286 30.5 938 
2006 10 1.1  616 65.2  319 33.8 945 
2007 13 1.3  652 63.3  365 35.4 1,030 
2008 10 1.0  612 59.7  403 39.3 1,025 
2009 11 1.2  661 69.9  273 28.9 945 
2010 11 1.1  697 68.4  311 30.5 1,019 
2011 15 1.5  636 64.7  332 33.8 983 
2000–11 160 1.4  7,837 67.6  3,594 31.0 11,591 
Note: Year of first insulin use is a proxy for year of diagnosis. 
Source: AIHW analysis of the NDR 2011. 
 
NDR coverage of type 1 diabetes in children 
The capture–recapture method (Box B2) was used with the two independent data sources 
(NDSS and APEG) to determine coverage of those aged 0–14 with type 1 diabetes on the 
NDR. Over the period 2000–11 it was estimated to be 99.4% (Table B.3). Based on this 
estimate it is expected that 73 cases were missed by both sources. 
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Table B3: Coverage of NDR registrants with type 1 diabetes and aged 
under 15 at diagnosis by year of diagnosis, 2000–11 
 
Total NDR 
registrants Missing cases(a) 
Coverage rate(b) 
(%) 
2000 833 7 99.2 
2001 894 6 99.3 
2002 937 6 99.4 
2003 1,030 5 99.5 
2004 1,012 6 99.4 
2005 938 6 99.3 
2006 945 5 99.5 
2007 1,030 7 99.3 
2008 1,025 7 99.4 
2009 945 5 99.5 
2010 1,019 5 99.5 
2011 983 8 99.2 
2000–11 11,591 73 99.4 
(a) Estimated number of missing cases using the capture–recapture method with the two independent  
data sources: NDSS and APEG. 
(b) Coverage rate = (NDR registrants/[NDR registrants + Estimated missing cases]) x100. 
Source: AIHW analysis of the NDR 2011. 
 
Box B2: Capture–recapture method 
The capture–recapture method as described by LaPorte et al. (1993) can be applied to the 
calculation of incidence rates of insulin-treated diabetes when multiple sources are being 
used to identify new cases. In capture–recapture, the cases provided by both sources (that 
is, the duplicates) provide important information about the degree to which cases may have 
been missed. The duplicates represent ‘recaptured’ people who have diabetes, and the 
degree of under-count can be estimated. The formula used to calculate ascertainment is 
below (see LaPorte et al. 1993 for more information). 
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where   
N = estimate of Number 
M = number in first sample (those marked) 
n = number in second sample 
m = number of ‘marked’ items in second sample 
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Diabetes type on the NDR 
As the symptoms of type 1 and type 2 diabetes may be similar, particularly in young adults, 
the recorded diabetes type is not always correct. Therefore, as part of processing information 
from the data sources, the reported diabetes is checked against a set of criteria and revised 
where necessary. The following algorithm (method of calculation) assesses and re-classifies 
reported diabetes type for some registrants on the NDSS (Box B3). 
The algorithm is based on age at diagnosis and the period between diagnosis and first 
insulin use because of the correlation with diabetes type. The algorithm has been updated 
several times over the years in consultation and agreement with the National Diabetes Data 
Working Group (NDDWG). Note that, with or without the algorithm, there will always be 
some level of misclassification.  
Additionally, in preparing the data for the NDR, 131 cases of type 2 diabetes in children 
diagnosed before 1990, and who started using insulin from 1999 onwards, were identified. 
The NDDWG advised that, in Australia, type 2 diabetes was unlikely to have been 
diagnosed in children before 1990 because at this time diabetes type was classified as either 
insulin-treated or non-insulin-treated and as juvenile-onset or adult-onset. Therefore, if the 
reported diabetes type was type 2 and the age at diagnosis was under 15 for anyone 
diagnosed before 1990, the diabetes type was considered not derivable. 
 
Box B3: Algorithm to derive diabetes type 
APEG only or APEG and NDSS records 
• If the record is sourced from APEG only, or from both APEG and NDSS, then the 
derived diabetes type is equal to the reported diabetes type. 
NDSS-only records 
If the record is sourced from NDSS only, if: 
• the reported diabetes type is type 1 and the age at diagnosis is missing, then the 
derived diabetes type is unable to be derived 
• the reported diabetes type is type 1 and the age at diagnosis is under 15:  
– if the time between diagnosis and first insulin use is missing, then the derived diabetes 
type is unable to be derived 
– if the time between diagnosis and first insulin use is more than 1 year, then the derived 
diabetes type is unable to be derived 
– if the time between diagnosis and first insulin use is less than or equal to 1 year, then 
the derived diabetes type equals type 1; that is, the reported diabetes type 
• the reported diabetes type is type 1 and the age at diagnosis is greater than or equal to 
15: 
– if the time between diagnosis and first insulin use is missing, then the derived diabetes 
type is unable to be derived 
 
(continued) 
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Box B3 (continued): Algorithm to derive diabetes type 
– if the time between diagnosis and first insulin use is more than 1 year, then the derived 
diabetes type equals type 2 
– if the time between diagnosis and first insulin use is less than or equal to 1 year, then 
the derived diabetes type equals type 1; that is, the reported diabetes type 
• the reported diabetes type is type 2: 
– if age at diagnosis is less than 10, then the derived diabetes type is unable to be derived 
(apart from individual cases that were confirmed by hospital records) 
– if the age at diagnosis is greater than or equal to 10, then the derived diabetes type 
equals type 2; that is, the reported diabetes type 
• the reported diabetes type is gestational diabetes: 
– if the age at diagnosis is under 14, then the derived diabetes type is unable to be 
derived 
– if the age at diagnosis is greater than or equal to 14 and under 50, then the derived 
diabetes type equals gestational diabetes; that is, the reported diabetes type 
– if the age at diagnosis is greater than or equal to 50, then the derived diabetes type 
equals type 2 
• the reported diabetes type is other diabetes, then the derived diabetes type equals 
other diabetes; that is, the reported diabetes type. 
 
Table B4 shows how applying the algorithm to reported diabetes type has re-classified the 
type for the 311,366 people who began using insulin between 2000 and 2011.  
 
Table B4: Reported and derived diabetes type of NDR registrants, 2000–11 
Reported diabetes 
type 
Derived diabetes type 
Type 1 Type 2 Gestational Other Not derived Total 
Type 1 26,578 9,693 . . . . 34,425 70,696 
Type 2 . . 208,755 . . . . 49 208,804 
Gestational . . 54 29,119 . . 15 29,188 
Other . . . . . . 2,521 . . 2,521 
Missing . . . . . . . . 157 157 
Total 26,578 218,502 29,119 2,521 34,646 311,366 
Source: AIHW analysis of the NDR 2011. 
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Derivation of variables 
When data were missing, inconsistent or illogical in the NDSS and APEG data sets, variables 
were derived using the process outlined in Box B4. 
 
Box B4: Derivation of variables used on the NDR 
Date of first insulin injection 
To derive a single date of first insulin injection using the APEG date of first insulin injection 
and the NDSS date of first insulin injection: 
• use APEG date of first insulin injection, or 
• if APEG date of first insulin injection is missing, use NDSS date of first insulin 
injection, or 
• if both dates are missing, then date is missing. 
Date of registration 
To derive a single date of registration using the APEG date of registration and the NDSS 
date of registration: 
• if two dates are the same, use either date, or 
• if one date is missing, use the other date, or 
• if two dates differ by less than 1 year, use the earlier date, or 
• if two dates differ by more than 1 year but one date of registration is within 1 year of 
the date of first insulin injection, use that date of registration, or 
• if two dates differ by more than 1 year and neither date is within 1 year of the date of 
first insulin injection, then date is missing. 
Date of first insulin use 
To derive a date of first insulin use for all people identified as insulin users using the 
derived date of first insulin injection and the date of first insulin purchase from the NDSS 
sales data: 
• if two dates are the same, use either date, or 
• if one date is missing, use the other date, or 
• if two dates are different, use the earlier date, or 
• if two dates are missing, then date is missing. 
 
(continued) 
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Box B4 (continued): Derivation of variables used on the NDR 
Date of diagnosis 
To derive a single date of diagnosis using the derived date of first insulin use, derived date 
of registration and NDSS date of diagnosis: 
APEG only or APEG and NDSS records 
• use date of first insulin injection, or 
• if date of first insulin injection is missing, use date of registration, or 
• if date of registration is missing, use NDSS date of diagnosis, or 
• if NDSS date of diagnosis is missing, then date is missing. 
NDSS only records 
• use NDSS date of diagnosis, or 
• if NDSS date of diagnosis is missing and reported diabetes type is gestational diabetes, 
use date of registration, or 
• if NDSS date of diagnosis is missing, then date is missing. 
Age at diagnosis 
To calculate age at diagnosis using the derived date of birth and derived date of diagnosis: 
• if date of birth is not missing and date of diagnosis is not missing, and date of birth is 
earlier than or equal to date of diagnosis, then age at diagnosis is calculated as the 
number of years between date of birth and date of diagnosis 
• otherwise, if date of diagnosis is earlier than date of birth by less than 1 month, then 
age at diagnosis is zero 
• otherwise, if date of diagnosis is earlier than date of birth by greater than or equal to 
1 month, or either date is missing, age at diagnosis is unable to be calculated. 
Time between diagnosis and first insulin use 
To calculate the time, in years, between the derived date of diagnosis and derived date of 
first insulin use: 
• if date of diagnosis is not missing and date of first insulin use is not missing, and date 
of diagnosis is earlier than or equal to date of first insulin use, then time between 
diagnosis and first insulin use is calculated as the number of years between date of 
diagnosis and date of first insulin use 
• otherwise, if date of first insulin use is earlier than date of diagnosis by less than 1 
month, then time between diagnosis and first insulin use is zero 
• otherwise, if date of first insulin use is earlier than date of diagnosis by greater than 
equal to 1 month, or either date is missing, time between diagnosis and first insulin use 
is unable to be calculated. 
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Data sources: Population data 
Estimated Resident Populations 
Throughout this report, population data were used to derive rates of diabetes incidence. 
Population data held by the AIHW are sourced from the Australian Bureau of Statistics 
(ABS) and are updated as revised or new estimates become available. All population 
estimates currently produced by ABS are based on a usual residence concept; that is, where 
people usually reside. These Estimated Resident Populations (ERPs) are derived from the 
ABS Census of Population and Housing and adjusted for deaths, births and net migration. 
The ERPs used in this report are based on the 2006 Census and include revised estimates for 
2007 to 2011. 
Australia’s Aboriginal and Torres Strait Islander population is calculated from the Census. 
However, because of the smaller Indigenous population, it is difficult to measure population 
changes accurately between census years using the method described above. Therefore, the 
ABS developed experimental estimates and projections based on the 2006 Census. All 
calculations of rates for Aboriginal and Torres Strait Islander people in this report use the 
Series B projected Indigenous populations for 2006 to 2011. 
Statistical methods 
Age-specific rates 
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group. It is 
calculated by dividing the number of events occurring in each specified age group by the 
corresponding ‘at risk’ population in the same age group, and then multiplying the result by 
a constant (for instance, 100,000) to derive the rate. 
Age- and sex-standardised rates 
Standardisation is a technique used to enhance the comparability of data from different 
populations or time periods by making adjustments for the confounding effects of 
compositional differences in structure between the populations or subpopulations being 
compared (Earyes 2008). In this report, age- and sex-standardised rates facilitate 
comparisons between populations at different time periods when trends in incidence of 
insulin-treated diabetes is analysed. This standardisation process effectively removes the 
influence of age and sex structure on the summary rate. 
This report uses the direct method of standardisation, whereby standardised rates are 
derived by applying the specific rates observed in the study population to a single standard 
population. The Australian population at 30 June 2001 (ABS 2013) was used for all age- and 
sex-standardisation analyses in this report. Five-year age groups were used for all age- and 
sex-standardisation analyses, with an upper age group of 85 and over.  
The calculation of direct age- and sex-standardised rates consists of three steps: 
• calculate the age specific rate for each age group by sex 
• calculate the expected number of cases in each age group by sex by multiplying the  
age-specific rates by the corresponding standard population for each age group by sex 
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• sum the expected number of cases in each age group by sex and divide this sum by the 
total of the standard population to give the age- and sex-standardised rate. 
Population groups 
Australian Statistical Geography Standard 
Geographic location was classified according to the ABS’s Australian Statistical Geography 
Standard (ASGS) 2011 Remoteness Areas, which groups geographic areas into categories. 
These categories are defined using the Accessibility/Remoteness Index for Australia 
(ARIA+). ARIA+ is a measure of the remoteness of a location from the services provided by 
large towns or cities. Accessibility is judged purely on distance to one of the metropolitan 
centres, so it provides a relative indication of how difficult it might be for residents to access 
certain services such as health care and education. 
The categories used in this publication are: 
• Major cities 
• Inner regional 
• Outer regional 
• Remote and very remote. 
It should be noted that some postcodes may not map to the 2011 Census-based concordances 
and were not included in relevant tables. Further, some postcodes may have changed 
remoteness area since the 2011 Census; however, they will still be included under the area 
they were assigned in 2011. 
Index of Relative Socio-Economic Disadvantage 
Socioeconomic classifications were based on the ABS Index of Relative Socio-Economic 
Disadvantage (IRSD). Geographic areas are assigned a score based on attributes such as low 
income, low educational attainment, high unemployment and jobs in relatively unskilled 
occupations. It does not refer to the socioeconomic situation of a particular individual, but 
instead refers to the area in which a person lives. A low score means an area has more low-
income families, people with little training and high unemployment, and may be considered 
disadvantaged relative to other areas with higher scores. Areas with high index scores may 
be considered less disadvantaged relative to other areas. It is important to note that high 
scores reflect a relative lack of disadvantage, rather than advantage, and that the IRSD relates 
to the average disadvantage of all people living in a geographic area and cannot be 
presumed to apply to all individuals living within the area.  
In this report, a person’s socioeconomic status was classified using their residential postcode 
according to the IRSD for 2011. Five population-based socioeconomic groups (fifths), based 
on the level of the index, were used for analyses, where group 1 represents the lowest SES 
fifth of the population and group 5 the highest SES. 
Geographic areas may be excluded where no score is determined due to low populations or 
high levels of non-response in the underlying census. Additionally, some postcodes may not 
map to these 2011 Census-based concordances and were also excluded. Lastly, some 
postcodes may have changed socioeconomic group since the 2011 Census; however, they 
will still be included under the area they were assigned in 2011. 
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Aboriginal and Torres Strait Islander status 
The NDR may underestimate the number of Aboriginal and Torres Strait Islander registrants 
with insulin-treated diabetes for a number of reasons including: 
• non-identification of Aboriginal or Torres Strait Islander origin 
• limitations in the collection of Indigenous status on the NDSS form before 2005 
• Indigenous people with diabetes not registering with the NDSS because they can access 
programs other than the NDSS to access diabetes-related products. 
Non-identification of Indigenous Aboriginal or Torres Strait Islander origin 
Identifying as being of Indigenous origin on both data sources of the NDR (APEG and 
NDSS) is voluntary. Among those who began using insulin in 2005–2011 and registered on 
the NDSS from 2005 onwards, the Indigenous status was not stated or inadequately 
described in 16% of cases. Note that there were 112,764 registrants who began to use insulin 
in the 2005–2011 period, but registered with the NDSS before 2005 and were excluded from 
analysis due to data quality issues. 
NDSS form limitations before 2005 
On the NDSS registration form before 2005, if the response to the Indigenous status question 
was not completed the registrant was recorded as non-Indigenous, rather than not stated. 
This may have overestimated the number of non-Indigenous registrants and consequently 
underestimated the number of Indigenous registrants.  
In early 2005, the NDSS database was amended so that an additional category indicated 
where the Indigenous status of the registrant was not-stated or was not well enough 
described so as to make a determination. Therefore, in the absence of information, ‘not 
stated’ became the default value (Health Data Standards Committee 2006). 
Accessing programs other than the NDSS 
Low registration rates for the NDSS, and subsequently the NDR, among Aboriginal and 
Torres Strait Islander people may be due to the ability of Indigenous people to access other 
programs. For example, programs such as Section 100 of the National Health Act 1953, 
Aboriginal Medical Services and the National Aboriginal Community Controlled Health 
Organisation are designed to provide access to the diabetes-related products that people 
with insulin-treated diabetes require.  
In addition, NDSS Access Points are not always available in remote areas, limiting access to 
NDSS services. 
Trend analysis 
Trend analysis has been presented only for type 1 diabetes because the requirement of 
insulin for this type of diabetes means that it is more likely that people with type 1 diabetes 
will be registered on the NDSS and actively purchasing products to administer insulin. 
Initial examination of the incidence of insulin-treated type 2 diabetes and insulin-treated 
gestational diabetes highlighted that interpretation of trends may be problematic because 
there were substantial increases in both type 2 diabetes and GDM in 2003 and 2010 (Figure 
B1). Several factors may have had an impact on the number of people captured by the 
database, resulting in the increases in insulin-use observed: 
• changing treatment regimens for the administration of insulin.  
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• a move towards universal screening for GDM escalating from 2005. In addition, from 
2009 to 2011 the NDSS initiated a GDM register accompanied with an educational 
campaign (Diabetes Australia 2013b). The implementation of these projects may have 
resulted in an increasing number of people being screened for GDM, and consequently 
registering with the NDSS. 
• the NDSS registration process itself, whereby health professionals may indicate on NDSS 
registration forms that a person is insulin-requiring in anticipation for the 
commencement of insulin treatment in future, which may not eventuate. See 
‘Determining who is on the NDR’ for more information about this. 
• potential impact of changes to the NDSS database system. The NDSS database has 
undergone two major structural changes: the new system implemented in 2002 
improved the data fields collected and in 2010, there was a change to the retention of 
historical information so that any alteration to information was not permanently 
overwritten. 
 
 
Note: The increase in the number of people beginning to use insulin in 2003 and 2010 is partly related to structural changes to the NDSS 
database in 2002 and 2010 resulting in improved levels of checking and information retention. 
Source: AIHW analysis of the NDR 2011. 
Figure B1: Derived incidence of insulin-treated diabetes, Australia 2000–11 
 
Joinpoint analysis 
A joinpoint regression model describes changing trends over successive segments of time 
and the amount of change within each segment. Trends are characterised by joined linear 
segments; a joinpoint is created where 2 segments meet, thus representing a statistically 
significant change in the trend. It is important to note that, although the joinpoint analysis 
identifies a particular point in time where a trend changes, in reality changes in trends are 
not usually abrupt, depending on the underlying cause of the change.  
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The joinpoint software takes trend data in the form of age-standardised rates and fits the 
simplest joinpoint model possible, where there is a minimum number of segments necessary 
to characterise a trend. The software begins with a model with zero joinpoints (that is, no 
changes in trend) and incrementally tests whether more joinpoints are statistically 
significant. The number of significant joinpoints is identified through performing several 
permutation tests and each p-value is found using Monte Carlo methods.  
The software used to perform joinpoint analysis was Joinpoint Version 3.4.3, developed by 
the Statistical Research and Applications Branch of the National Cancer Institute in the 
United States of America (National Cancer Institute 2011). This software has been used 
frequently in the diabetes field to examine trends (Eurich et al. 2008; Wang et al. 2006; 
Yangfeng et al. 2012). 
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Glossary 
blood glucose: The main sugar that the body makes from food. Glucose is carried though the 
bloodstream to provide energy to all cells in the body. Cells cannot use glucose without the 
help of insulin. 
diabetes: A chronic condition in which the body is unable to regulate its blood glucose 
(sugar), the main source of energy for the body’s cells. The pancreas makes the hormone 
insulin, which controls the amount of glucose in the blood and moves it from the blood into 
the cells where it is converted into energy or stored until needed. When glucose is absorbed 
into the bloodstream, it stimulates the pancreas to produce insulin. Diabetes occurs when the 
pancreas is unable to make sufficient insulin, or when the body does not respond adequately 
to insulin. 
diabetic ketoacidosis: in the absence of insulin, glucose is unavailable as an energy source 
for the body’s needs and fat is broken down for use as an alternative energy source. This 
breakdown of fat results in an accumulation of ketones, and an increased acidity of the 
blood, which can be life-threatening if not treated. 
gestational diabetes: Gestational diabetes mellitus (GDM) develops in some women during 
pregnancy but usually passes when the pregnancy is over. However, women who have had 
GDM are at greater risk of developing type 2 diabetes later in life. GDM also increases the risk 
of perinatal morbidity and mortality. Women who had their diabetes diagnosed before a 
pregnancy do not fall into this category. 
hypoglycaemia: Low blood glucose level, which occurs if the person with diabetes has 
injected too much insulin, eaten too much food, had too much alcohol or exercised without 
additional food. 
incidence: The number of new cases (of an illness or event) occurring during a given period. 
insulin: A hormone produced by the pancreas, its main action is to enable body cells to 
absorb glucose from the blood and use it for energy. 
insulin-treated diabetes: All types of diabetes treated with insulin; includes type 1, type 2, 
gestational and other types of diabetes. It is a term used to describe those on the NDR and is 
not a standard classification used in clinical practice. 
other types of diabetes: There are a number of conditions or syndromes that come under 
this category, such as genetic defects of beta-cell function, endocrine diseases and infections; 
these are relatively uncommon. 
type 1 diabetes: Mostly arises in childhood or young adults, though it can occur at any age. 
It is marked by the inability to produce insulin. People with type 1 diabetes need insulin 
replacement for survival. Most cases are caused by an autoimmune condition that destroys 
the pancreatic cells that produce insulin. 
type 2 diabetes: The most common form of diabetes, and occurs mostly in people aged 40 
and over. People with type 2 diabetes produce insulin but may not produce enough or 
cannot use it effectively. Some cases may be managed with changes to diet along with 
increased exercise and weight loss. Many cases require drugs as well, namely oral glucose-
lowering drugs that work on the pancreas. Many others require insulin in addition to other 
treatments. 
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Incidence of insulin-treated diabetes in Australia 2000–2011 
presents the latest available national data on new cases 
of insulin-treated diabetes from australia’s National 
Diabetes register. 
in 2011, there were 2,367 new cases of type 1 diabetes 
in australia, equating to 11 new cases per 100,000 
population. this rate has remained stable over the last 
decade, with between 10 and 12 new cases per 100,000 
population per year.
